2024. Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s306. DOI:https://doi.org/10.25251/skin.8.supp.306.